Atossa Genetics (ATOS)
(Delayed Data from NSDQ)
$1.42 USD
+0.05 (3.65%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.42 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
ATOS 1.42 +0.05(3.65%)
Will ATOS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATOS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATOS
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
ATOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Other News for ATOS
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
Atossa Therapeutics: A Promising Buy in Oncology with Strong Financials and Upcoming Trial Milestones
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024
Texas probes CenterPoint, Starbucks in talks with Elliott: Morning Buzz